# Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

> **NCT00735917** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 19 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** saracatinib
- **OTHER:** pharmacogenomic studies
- **OTHER:** pharmacological study
- **PROCEDURE:** positron emission tomography
- **RADIATION:** fludeoxyglucose F 18
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00735917
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-04
- **Final completion:** 2012-10
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2019-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00735917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00735917, "Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00735917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*